First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis

Table 2 Cost-effectiveness analysis

Strategies	Life years	Total costs ($)	QALYs	ICER, $/QALY
A
NI	2.01	46,362	1.30	375,656
C	1.89	8339	1.20
Incremental (NI vs. C)	0.12	38,023	0.10
E
NI	2.01	46,598	1.44	327,943
C	1.89	8596	1.33
Incremental (NI vs. C)	0.12	38,002	0.12
N
NI	2.01	46,232	1.24	115,495
C	1.89	7689	0.90
Incremental (NI vs. C)	0.12	38,543	0.33

QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio, A All randomized patients, E Patients with epithelioid histology, N Patients with non-epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin

ISSN: 1750-1172